Shamburg News · 8-K filed Nov 18, 2026, 11:08 AM EST

Drugs Made in America Acquisition II Consolidates Investor Notes; Proposes Alpha AI Biotech Deal

DMII · Drugs Made In America Acquisition II Corp.

  • Financing
  • Other event
  • Acquisition
  • Material agreement
  • Materiality: high

Drugs Made in America Acquisition II Corp. disclosed that its investor funded a further $250,000 under a $1,400,000 convertible notes financing on November 6, 2026, bringing funded amounts to $700,000. The Bridge Note and Second Note are to be consolidated into a $700,000 convertible promissory note maturing June 30, 2027, convertible at a 35% discount to market upon a business combination. The company also delivered a nonbinding preliminary proposal to Alpha AI Biotech Group on October 29, 2026, contemplating a $600 million pre-money valuation payable in 60,000,000 shares at $10.00, with a limited 30-day standstill approved November 3, 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.03, 8.01, 9.01, accession 0001477932-26-007137.

Written from the filing by Shamburg Markets. Figures are as reported by the company.